H.C. Wainwright analyst Robert Burns raised the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $26 and keeps a Buy rating on the shares. The firm says NX-5948 demonstrated a “highly encouraging response” rate in Waldenstrom’s macroglobulinemia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics Appoints Anil Kapur to Board
- Nurix Therapeutics price target raised to $35 from $30 at Oppenheimer
- Boeing to cut 10% of workforce, Lundbeck to acquire Longboard: Morning Buzz
- Nurix Therapeutics Braces for Stricter Disclosure Rules as Market Value Grows
- Nurix Therapeutics reports Q3 EPS (67c), consensus (69c)